术前氯吡格雷对孤立性冠脉搭桥结局的影响:STS国家数据库分析
基于STS国家数据库148,317例孤立性CABG分析,19,553例(13.2%)在术前5天内使用氯吡格雷。氯吡格雷组手术死亡率轻度升高(2.8% vs 2.1%,P < .001),纵隔再探查(3.5% vs 2.1%,P < .001)和血制品使用(72.7% vs 56.8%,P < .001)更高。风险随停药时间延长而降低,3天后趋于平台;第3天手术与第5天结局相当。
要点
- 术前5天内使用氯吡格雷与手术死亡率轻度升高相关(2.8% vs 2.1%)。
- 氯吡格雷组纵隔再探查和血制品使用率显著高于对照组。
- 再探查风险在停药第0天最高,第3天后趋于平台;第3天手术与第5天结局相当。
核心结论
- 术前5天内使用氯吡格雷行CABG与手术死亡率轻度升高、再探查出血增加及血制品使用大幅增加相关。
- 风险随停药时间延长而降低,停药3天后趋于平台;第3天手术与第5天结局相当,可缩短等待期。
研究设计与样本
- 基于STS国家数据库的回顾性分析,纳入148,317例孤立性CABG患者。
- 按术前5天内是否使用氯吡格雷分组,并按末次给药天数(0至5天)分层;对照组为术前5天内未使用氯吡格雷者。
主要发现
- 氯吡格雷组手术死亡率为2.8%,对照组为2.1%(P < .001)。
- 氯吡格雷组纵隔再探查率为3.5%,对照组为2.1%(P < .001)。
- 氯吡格雷组血制品使用率为72.7%,对照组为56.8%(P < .001)。
- 手术死亡率调整后比值比在给药当天达峰值,此后与对照组相当。
- 再探查比值比在第0天最高,逐渐下降至第3天后平台;第3天手术与第5天相比,手术死亡率和再探查比值比相似,总住院时间和术前住院时间更短,但血制品使用更高。
临床怎么用
- 术前5天内使用氯吡格雷的CABG患者手术死亡率和再探查出血风险轻度增加,血制品使用大幅增加。
- 停药后风险随时间降低,3天后趋于平台;第3天手术与第5天结局相当,可考虑缩短等待期。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We analyzed The Society of Thoracic Surgeons Database to investigate risks and optimal timing for coronary artery bypass grafting (CABG) after clopidogrel administration. METHODS: Patients were categorized based on clopidogrel use within 5 days and further stratified by days from the last dose (0 to 5 days). Controls were patients who did not receive clopidogrel within 5 days of surgery. The primary outcome was operative mortality, and secondary outcomes included mediastinal reexploration for bleeding and blood product use. RESULTS: Among 148,317 isolated CABG, 19,553 patients (13.2%) received clopidogrel within 5 days. Minimal differences in operative mortality (2.8% vs 2.1%, P < .001), but higher rates of mediastinal reexploration (3.5% vs 2.1%, P < .001) and blood product utilization (72.7% vs 56.8%, P < .001) were observed in the clopidogrel group. The adjusted odds ratio of operative mortality peaked on the day of clopidogrel administration but was comparable to controls thereafter. The odds of reexploration were highest on day 0, decreasing gradually to a plateau after day 3. Patients who underwent operations on day 3 after clopidogrel administration had similar odds of operative mortality and mediastinal reexploration for bleeding and shorter total and preoperative lengths of stay but higher blood product use compared with day 5. CONCLUSIONS: CABG within 5 days from clopidogrel is associated with a modest increase in operative mortality and reexploration for bleeding and a substantial increase in blood product use. Risks decreased with increasing time from discontinuation, plateauing after 3 days from clopidogrel. CABG at 3 days yields comparable outcomes as 5 days, reducing the waiting period.
引用
- Choi K, Schaff HV, Villavicencio MA, et al. Effect of Preoperative Clopidogrel on Outcomes of Isolated Coronary Artery Bypass Graft: An STS National Database Analysis. Ann Thorac Surg. 2024. PMID: 39067633. doi:10.1016/j.athoracsur.2024.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。